Presentation of the attention-grabbing case of a affected person affected by castrate-resistant prostate most cancers (CRPC) with bone metastasis, who obtained concomitant treatment with abiraterone acetate (AA) and radium-223. The affected person skilled important scientific enchancment in his high quality of life and ache aid after starting the aforementioned treatment, with out being affected by opposed toxicities.
Currently, the appropriate choice of sufferers to obtain radium-223 treatment remains to be a scientific problem in the case of CRPC with metastasis. In this text, we talk about the future prospects of this treatment, reviewing present evidence about concomitant therapies with radium-223 and its current state, primarily based upon the current suggestions from the Pharmacovigilance Risk Assessment Committee (PRAC), and the knowledge offered in the ERA-223 examine.
Based on our scientific expertise, we offer sensible orientation for the integration of this radiopharmaceutical in the therapeutic plan for this group of sufferers. We conclude, regardless of some of the constructive outcomes and our wonderful expertise, that it will be clever to attend for the outcomes of the scientific trials which are finding out the security and advantages of the combined use of radium-223 with new hormone therapies.
Bearing in thoughts that to this point, the solely revealed large-scale randomised trial that investigated the mixture of AR-axis-targeted remedy with Ra-223 is unfavourable, the harms of the mixture outweighed any advantages in ERA-223. Nonetheless, with a purpose to advocate whether or not or not this treatment must be used, it’s important to outline the affected person profile that would profit from this therapeutic possibility.
Radium 223 combined with new hormone therapies for the treatment of castrate-resistant metastatic prostate most cancers: scientific evidence and sharing of our expertise.
Use and affect of the prehospital 12-lead ECG in the main PCI period (PHECG2): protocol for a mixed-method examine.
Use of the prehospital 12-lead ECG (PHECG) is really useful in sufferers presenting to emergency medical providers (EMS) with suspected acute coronary syndrome (ACS).
Prior analysis discovered that though PHECG use was related with improved 30-day survival, a 3rd of sufferers (usually girls, the aged and these with comorbidities) beneath EMS care didn’t obtain a PHECG.The general intention of the PHECG2 examine is to replace evidence on care and outcomes for sufferers eligible for PHECG, particularly addressing the following analysis questions:(1) Is there a distinction in 30-day mortality, and in reperfusion price, between those that do and those that don’t obtain PHECG? (2) Has the proportion of eligible sufferers who obtain PHECG modified since the introduction of main percutaneous coronary intervention networks? (3) Are sufferers that obtain PHECG totally different from these that don’t in phrases of social and demographic elements, or prehospital scientific presentation? (4) What elements affect EMS clinicians’ selections to carry out PHECG?This is an explanatory, mixed-method examine comprising 4 work packages (WPs). WP1 is a population-based, linked-data evaluation of a nationwide ACS registry (Myocardial Ischaemia National Audit Project). WP2 is a retrospective chart overview of affected person information from three giant regional EMS. WP3 contains focus teams of EMS personnel.
Description: A polyclonal antibody against NOD1. Recognizes NOD1 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:5000, IHC:1:50-1:200
Description: A polyclonal antibody against NOD1. Recognizes NOD1 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:5000, IHC:1:50-1:200
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human NOD1 . This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human NOD1 . This antibody is tested and proven to work in the following applications:
Description: This gene encodes a member of the NOD (nucleotide-binding oligomerization domain) family. This member is a cytosolic protein. It contains an N-terminal caspase recruitment domain (CARD), a centrally located nucleotide-binding domain (NBD), and 10 tandem leucine-rich repeats (LRRs) in its C terminus. The CARD is involved in apoptotic signaling, LRRs participate in protein-protein interactions, and mutations in the NBD may affect the process of oligomerization and subsequent function of the LRR domain. This protein is an intracellular pattern-recognition receptor (PRR) that initiates inflammation in response to a subset of bacteria through the detection of bacterial diaminopimelic acid. Multiple alternatively spliced transcript variants differring in the 5' UTR have been described, but the full-length nature of these variants has not been determined.
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human NOD1 (C-Terminus). This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human NOD1 (aa930-949). This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human NOD1 (C-term). This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Mouse Nod1 (Center). This antibody is tested and proven to work in the following applications:
Description: Pre-made over-expression lentivirus for expressing human target: h NOD1 (nucleotide-binding oligomerization domain containing 1), [alternative names: CARD4; CLR7.1; NLRC1]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_006092. It also contains a RFP-Blasticidin dual selection marker.
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human NOD1 / CARD4 (C-Term). This antibody is tested and proven to work in the following applications:
Description: Quantitativesandwich ELISA kit for measuring Human Nucleotide-binding oligomerization domain-containing protein 1 (NOD1) in samples from serum, plasma, tissue homogenates, cell lysates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.
Human Nucleotide-binding oligomerization domain-containing protein 1(NOD1) ELISA kit
Description: Quantitativesandwich ELISA kit for measuring Human Nucleotide-binding oligomerization domain-containing protein 1(NOD1) in samples from serum, plasma, tissue homogenates, cell lysates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.
Mouse Nucleotide-Binding Oligomerization Domain-Containing Protein 1 (NOD1) ELISA Kit
Description: A Rabbit polyclonal antibody against Human Nucleotide Binding Oligomerization Domain Containing Protein 1 (NOD1). This antibody is labeled with APC.
Description: A Rabbit polyclonal antibody against Human Nucleotide Binding Oligomerization Domain Containing Protein 1 (NOD1). This antibody is labeled with Biotin.
Description: A Rabbit polyclonal antibody against Human Nucleotide Binding Oligomerization Domain Containing Protein 1 (NOD1). This antibody is labeled with Cy3.
Description: A Rabbit polyclonal antibody against Human Nucleotide Binding Oligomerization Domain Containing Protein 1 (NOD1). This antibody is labeled with FITC.
Description: A Rabbit polyclonal antibody against Human Nucleotide Binding Oligomerization Domain Containing Protein 1 (NOD1). This antibody is labeled with HRP.
Nucleotide Binding Oligomerization Domain Containing Protein 1 (NOD1) Polyclonal Antibody (Human), PE
Description: A Rabbit polyclonal antibody against Human Nucleotide Binding Oligomerization Domain Containing Protein 1 (NOD1). This antibody is labeled with PE.
Rabbit Anti-Human Nod1 (Apaf-1 like protein/CARD4) IgG #1, aff pure
Description: A Rabbit polyclonal antibody against Human Nucleotide Binding Oligomerization Domain Containing Protein 1 (NOD1). This antibody is labeled with APC-Cy7.
WP4 will synthesise findings from WP1-Three to tell the growth of an intervention to extend PHECG uptake.The examine has been accepted by the London-Hampstead Research Ethics Committee (ref: 18LO1679). Findings shall be disseminated via suggestions to collaborating EMS, convention displays and publication in peer-reviewed journals.NCT03699137.
Background: Brain radiotherapy is the usual remedy possibility for a number of mind metastases (BMs) from non-small cell lung most cancers (NSCLC), particularly in the absence of a driver mutation. However, the prognosis for such sufferers stays poor. Apatinib is a potent antiangiogenic compound directed on the vascular endothelial progress issue receptor-2 (VEGFR-2); nevertheless, to date, there are not any investigations of apatinib concurrent with mind radiotherapy for NSCLC sufferers with BMs.
We report a case of EGFR wild-type and ALK-negative lung adenocarcinoma affected person with a number of symptomatic BMs, who obtained apatinib along with mind radiation remedy. A positive oncologic consequence was achieved for each mind metastatic lesions and the first pulmonary tumor. Case Presentation: A 61-year-old feminine (by no means smoker) who initially offered with headache and dizziness was recognized with lung adenocarcinoma with a number of mind metastasis (cT2aN3M1b stage IV), and was unfavorable for EGFR and ALK.
The affected person refused to obtain chemotherapy and was solely amenable to mind radiotherapy and focused remedy. After approval from the institutional ethics committee, she underwent concurrent oral apatinib (500 mg/day) with complete mind radiation remedy (WBRT) (37.5Gy) with simultaneous in-field increase (49.5Gy) in 15 fractions with picture guided intensity-modulated radiotherapy.
Three weeks later, neurologic signs totally ceased and a partial response (PR) for the BMs with near-complete decision of peritumoral mind edema was achieved. Chest CT carried out on the identical time and confirmed shrinkage of the lung main with a PR.
The affected person suffered grade III oral mucositis one week after mind radiotherapy and refused additional apatinib. At 12 months after mind radiotherapy, the mind tumors remained properly managed. Conclusions: This is the primary identified documentation of a speedy medical response of apatinib concurrent with mind radiotherapy in a lung adenocarcinoma affected person with symptomatic a number of BMs. Apatinib mixed with mind radiotherapy could possibly be another remedy possibility for BMs from NSCLC, particularly for these with no driver mutation. Further medical trials are required to corroborate this discovery.
Clinical Response to Apatinib Combined With Brain Radiotherapy in EGFR Wild-Type and ALK-Negative Lung Adenocarcinoma With Multiple Brain Metastases.
Pattern of Pediatric Supracondylar Fracture Operated at A Rural Teaching Hospital of Nepal: A Descriptive Cross-sectional Study.
Supracondylar fracture of humerus is likely one of the frequent pediatric fractures encountered in our every day medical observe. The goal of this examine is to decide the sample of supracondylar fracture operated at rural educating hospital of Jumla, Karnali Nepal.A descriptive cross sectional examine was carried out at Jumla, Karnali after Institutional Review Committee approval.
Operating room notes from 15 May 2017 to 16 November 2019 had been retrieved to collect the next data: sufferers tackle, age, intercourse, aspect, harm mechanism, displacement, neurovascular harm, concurrent accidents, preliminary administration by conventional bone setters, time between harm and surgical procedure, operative method.
Description: A polyclonal antibody against NOD2. Recognizes NOD2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200
Description: A polyclonal antibody against NOD2. Recognizes NOD2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:2000, IHC:1:25-1:100
Buffer: Preservative: 0.03% Proclin 300 Constituents: 50% Glycerol, 0.01M PBS, pH 7.4 >95%, Protein G purified
Description: A polyclonal antibody against NOD2. Recognizes NOD2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC, IF; Recommended dilution: IHC:1:20-1:200, IF:1:50-1:200
Description: A polyclonal antibody against NOD2. Recognizes NOD2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human NOD2 . This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human NOD2 . This antibody is tested and proven to work in the following applications:
Buffer: Preservative: 0.03% Proclin 300 Constituents: 50% Glycerol, 0.01M PBS, pH 7.4 >95%, Protein G purified
Description: A polyclonal antibody against NOD2. Recognizes NOD2 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA
Buffer: Preservative: 0.03% Proclin 300 Constituents: 50% Glycerol, 0.01M PBS, pH 7.4 >95%, Protein G purified
Description: A polyclonal antibody against NOD2. Recognizes NOD2 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA
Buffer: Preservative: 0.03% Proclin 300 Constituents: 50% Glycerol, 0.01M PBS, pH 7.4 >95%, Protein G purified
Description: A polyclonal antibody against NOD2. Recognizes NOD2 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA
Description: Pre-made over-expression lentivirus for expressing human target: NOD2 (nucleotide-binding oligomerization domain containing 2), [alternative names: ACUG; BLAU; CARD15; CD; CLR16.3; IBD1; NLRC2; NOD2B; PSORAS1]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_022162.1. It also contains a RFP-Blasticidin dual selection marker.
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human NOD2 / CARD15 (N-Terminus). This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human NOD2 / CARD15 (C-Terminus). This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human Goat Anti-CARD15 / NOD2 (Internal) . This antibody is tested and proven to work in the following applications:
Description: Quantitativesandwich ELISA kit for measuring Human Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) in samples from serum, plasma, asciticfluid, tissue homogenates, cell lysates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.
Human Nucleotide-binding oligomerization domain-containing protein 2(NOD2) ELISA kit
Description: Quantitativesandwich ELISA kit for measuring Human Nucleotide-binding oligomerization domain-containing protein 2(NOD2) in samples from serum, plasma, asciticfluid, tissue homogenates, cell lysates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.
Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) CLIA Kit
The Intra-assay Precision is determined when 3 samples with low, middle and high level of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) were tested on 3 different plates, 8 replicates in each plate
Description: This is Double-antibody Sandwich Chemiluminescent immunoassay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in Tissue homogenates, cell lysates and other biological fluids.
Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2)CLIA Kit
The Intra-assay Precision is determined when 3 samples with low, middle and high level of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) were tested on 3 different plates, 8 replicates in each plate
Description: This is Double-antibody Sandwich Chemiluminescent immunoassay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in Tissue homogenates, cell lysates and other biological fluids.
Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2)CLIA Kit
The Intra-assay Precision is determined when 3 samples with low, middle and high level of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) were tested on 3 different plates, 8 replicates in each plate
Description: This is Double-antibody Sandwich Chemiluminescent immunoassay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in Tissue homogenates, cell lysates and other biological fluids.
Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2)CLIA Kit
The Intra-assay Precision is determined when 3 samples with low, middle and high level of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) were tested on 3 different plates, 8 replicates in each plate
Description: This is Double-antibody Sandwich Chemiluminescent immunoassay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in Tissue homogenates, cell lysates and other biological fluids.
Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) CLIA Kit
Description: Double-antibody Sandwich chemiluminescent immunoassay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2)Tissue homogenates, cell lysates and other biological fluids
Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) ELISA Kit
The Intra-assay Precision is determined when 3 samples with low, middle and high level of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) were tested on 3 different plates, 8 replicates in each plate
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in tissue homogenates, cell lysates and other biological fluids.
Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) ELISA Kit
The Intra-assay Precision is determined when 3 samples with low, middle and high level of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) were tested on 3 different plates, 8 replicates in each plate
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in tissue homogenates, cell lysates and other biological fluids.
Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) ELISA Kit
The Intra-assay Precision is determined when 3 samples with low, middle and high level of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) were tested on 3 different plates, 8 replicates in each plate
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in tissue homogenates, cell lysates and other biological fluids.
Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) ELISA Kit
The Intra-assay Precision is determined when 3 samples with low, middle and high level of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) were tested on 3 different plates, 8 replicates in each plate
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in tissue homogenates, cell lysates and other biological fluids.
Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) ELISA Kit
Description: Enzyme-linked immunosorbent assay based on the Double-antibody Sandwich method for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in samples from tissue homogenates, cell lysates and other biological fluids with no significant corss-reactivity with analogues from other species.
ELISA kit for Human NOD2 (Nucleotide Binding Oligomerization Domain Containing Protein 2)
The microtiter plate provided in this kit has been pre-coated with an antibody specific to Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2). Standards or samples are then added to the appropriate microtiter plate wells with a bio
Description: A sandwich ELISA kit for detection of Nucleotide Binding Oligomerization Domain Containing Protein 2 from Human in samples from blood, serum, plasma, cell culture fluid and other biological fluids.
Data evaluation was performed utilizing Statistical Package for Social Sciences model 20.Left aspect predominated with 88 (63.7%) and extension kind was frequent in 135 (97.8%). Thirteen (9.4%) sufferers had been initially managed by conventional bonesetters. A complete of 138 kids underwent operative fixation with imply age of seven.47 years and gender ratio of two:1 boy to woman.
Fall from cliff, ladders and rooftops had been the prevailing explanation for harm 73 (52.8%). Average time between harm and surgical procedure was 5.2 days. Closed discount was performed in 100 (72.4%) sufferers whereas open discount was crucial in 38 (27.5%) sufferers.Closed extension kind pediatric supracondylar fracture was frequent in this examine. Fall from cliff, rooftop and ladder are the most important explanation for fracture. Delayed presentation and preliminary administration of the fracture by the standard bonesetters makes supracondylar fracture tougher in useful resource restricted setting like ours.
Merkel cell carcinoma (MCC) is a cutaneous neuroendocrine malignancy with a propensity for regional and distant unfold. Because of the relative infrequency of this illness, the patterns of metastasis in MCC are understudied.Patients with American Joint Committee on Cancer (eighth version) stage I-IV MCC handled at our establishment were recognized (1/1/2008-2/28/2018). The first web site of metastasis was categorized as regional [regional lymph node (LN) basin, in-transit] or distant. Distant metastasis-free (DMFS) and MCC-specific (MSS) survival have been estimated.
Results
Of 133 sufferers, 64 (48%) had stage I, 13 (10%) stage II, 48 (36%) stage III, and eight (6%) stage IV illness at presentation. The median follow-up time in sufferers who remained alive was 36 (interquartile vary 20-66) months. Regional or distant metastases developed in 78 (59%) sufferers. The first web site was regional in 87%, together with 73% with remoted LN involvement, and distant in 13%. Thirty-seven (28%) sufferers ultimately developed distant illness, which mostly concerned the belly viscera (51%) and distant LNs (46%) first.
The lung (0%) and mind (3%) have been not often the primary distant websites. Stage III MCC at presentation was considerably related to worse DMFS (hazard ratio 4.87, P = 0.001) and stage IV illness with worse MSS (hazard ratio 6.30, P = 0.002).Regional LN metastasis is the commonest first metastatic occasion in MCC, confirming the significance of nodal analysis. Distant illness unfold seems to have a predilection for sure websites. Understanding these patterns might assist to information surveillance methods.
Patterns of Metastasis in Merkel Cell Carcinoma.
Coronavirus Disease-19 (COVID-19) related to extreme acute pancreatitis: Case report on three relations.
Abdominal ache is one of the recognized signs related to coronavirus illness 2019. Little is thought in regards to the growth of acute pancreatitis as a complication of extreme acute respiratory syndrome coronavirus 2 an infection. This case report describes the presentation of acute pancreatitis in two of three relations with extreme COVID-19 an infection.
Data have been collected from three relations admitted with COVID-19 to the intensive care unit in March 2020. This research was reviewed and accepted by the native information and ethics committee (31-1521-253).
Description: A polyclonal antibody against NOD2. Recognizes NOD2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200
Description: A polyclonal antibody against NOD2. Recognizes NOD2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:2000, IHC:1:25-1:100
Buffer: Preservative: 0.03% Proclin 300 Constituents: 50% Glycerol, 0.01M PBS, pH 7.4 >95%, Protein G purified
Description: A polyclonal antibody against NOD2. Recognizes NOD2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC, IF; Recommended dilution: IHC:1:20-1:200, IF:1:50-1:200
Description: A polyclonal antibody against NOD2. Recognizes NOD2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human NOD2 . This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human NOD2 . This antibody is tested and proven to work in the following applications:
Buffer: Preservative: 0.03% Proclin 300 Constituents: 50% Glycerol, 0.01M PBS, pH 7.4 >95%, Protein G purified
Description: A polyclonal antibody against NOD2. Recognizes NOD2 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA
Buffer: Preservative: 0.03% Proclin 300 Constituents: 50% Glycerol, 0.01M PBS, pH 7.4 >95%, Protein G purified
Description: A polyclonal antibody against NOD2. Recognizes NOD2 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA
Buffer: Preservative: 0.03% Proclin 300 Constituents: 50% Glycerol, 0.01M PBS, pH 7.4 >95%, Protein G purified
Description: A polyclonal antibody against NOD2. Recognizes NOD2 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA
Description: Pre-made over-expression lentivirus for expressing human target: NOD2 (nucleotide-binding oligomerization domain containing 2), [alternative names: ACUG; BLAU; CARD15; CD; CLR16.3; IBD1; NLRC2; NOD2B; PSORAS1]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_022162.1. It also contains a RFP-Blasticidin dual selection marker.
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human NOD2 / CARD15 (N-Terminus). This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human NOD2 / CARD15 (C-Terminus). This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human Goat Anti-CARD15 / NOD2 (Internal) . This antibody is tested and proven to work in the following applications:
Description: Quantitativesandwich ELISA kit for measuring Human Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) in samples from serum, plasma, asciticfluid, tissue homogenates, cell lysates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.
Human Nucleotide-binding oligomerization domain-containing protein 2(NOD2) ELISA kit
Description: Quantitativesandwich ELISA kit for measuring Human Nucleotide-binding oligomerization domain-containing protein 2(NOD2) in samples from serum, plasma, asciticfluid, tissue homogenates, cell lysates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.
Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) CLIA Kit
The Intra-assay Precision is determined when 3 samples with low, middle and high level of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) were tested on 3 different plates, 8 replicates in each plate
Description: This is Double-antibody Sandwich Chemiluminescent immunoassay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in Tissue homogenates, cell lysates and other biological fluids.
Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2)CLIA Kit
The Intra-assay Precision is determined when 3 samples with low, middle and high level of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) were tested on 3 different plates, 8 replicates in each plate
Description: This is Double-antibody Sandwich Chemiluminescent immunoassay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in Tissue homogenates, cell lysates and other biological fluids.
Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2)CLIA Kit
The Intra-assay Precision is determined when 3 samples with low, middle and high level of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) were tested on 3 different plates, 8 replicates in each plate
Description: This is Double-antibody Sandwich Chemiluminescent immunoassay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in Tissue homogenates, cell lysates and other biological fluids.
Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2)CLIA Kit
The Intra-assay Precision is determined when 3 samples with low, middle and high level of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) were tested on 3 different plates, 8 replicates in each plate
Description: This is Double-antibody Sandwich Chemiluminescent immunoassay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in Tissue homogenates, cell lysates and other biological fluids.
Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) CLIA Kit
Description: Double-antibody Sandwich chemiluminescent immunoassay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2)Tissue homogenates, cell lysates and other biological fluids
Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) ELISA Kit
The Intra-assay Precision is determined when 3 samples with low, middle and high level of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) were tested on 3 different plates, 8 replicates in each plate
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in tissue homogenates, cell lysates and other biological fluids.
Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) ELISA Kit
The Intra-assay Precision is determined when 3 samples with low, middle and high level of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) were tested on 3 different plates, 8 replicates in each plate
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in tissue homogenates, cell lysates and other biological fluids.
Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) ELISA Kit
The Intra-assay Precision is determined when 3 samples with low, middle and high level of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) were tested on 3 different plates, 8 replicates in each plate
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in tissue homogenates, cell lysates and other biological fluids.
Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) ELISA Kit
The Intra-assay Precision is determined when 3 samples with low, middle and high level of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) were tested on 3 different plates, 8 replicates in each plate
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in tissue homogenates, cell lysates and other biological fluids.
Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) ELISA Kit
Description: Enzyme-linked immunosorbent assay based on the Double-antibody Sandwich method for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in samples from tissue homogenates, cell lysates and other biological fluids with no significant corss-reactivity with analogues from other species.
ELISA kit for Human NOD2 (Nucleotide Binding Oligomerization Domain Containing Protein 2)
The microtiter plate provided in this kit has been pre-coated with an antibody specific to Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2). Standards or samples are then added to the appropriate microtiter plate wells with a bio
Description: A sandwich ELISA kit for detection of Nucleotide Binding Oligomerization Domain Containing Protein 2 from Human in samples from blood, serum, plasma, cell culture fluid and other biological fluids.
Two of the three relations have been recognized with acute pancreatitis related to SARS-CoV-2. Other causes of acute pancreatitis have been excluded for each sufferers (together with alcohol, biliary obstruction/gall stones, medication, trauma, hypertriglyceridemia, hypercalcemia, and hypotension).These circumstances spotlight acute pancreatitis as a complication related to COVID-19 and underlines the significance of measuring pancreas-specific plasma amylase in sufferers with COVID-19 and belly ache.
)
)
)
)
 (pORF))
 (pORF))
 (pORF))
)
)
)
)
 (Target 1))
 (Target 2))
 (Target 3))
 (Target 1))
 (Target 2))
 (Target 3))
 (Target 1))
 (Target 2))
 (Target 3))
 (pPB-C-His))
 (pPB-N-His))
 (pPM-C-HA))
 (pPM-C-His))
 (pPB-C-His))
 (pPB-N-His))
 (pPM-C-HA))
 (pPM-C-His))
 (pPB-C-His))
 (pPB-N-His))
 (pPM-C-HA))
 (pPM-C-His))
 (CMV) (pLenti-GIII-CMV))
 (UbC) (pLenti-GIII-UbC))
 (EF1a) (pLenti-GIII-EF1a))
 Antibody)
 Antibody)
)
 Protein)
)
)
)
 ELISA kit)
 ELISA Kit)
 ELISA Kit)
 (Target 1))
 (Target 2))
 (Target 3))
 Control/blocking peptide #1)
 antiserum #1)
 (CMV) (pLenti-GIII-CMV-C-term-HA))
 (CMV) (pLenti-GIII-CMV-GFP-2A-Puro))
 (CMV) (pLenti-GIII-CMV-RFP-2A-Puro))
 (Target 1))
 (Target 2))
 (Target 3))
 (Target 1))
 (Target 2))
 (Target 3))
 Polyclonal Antibody (Human))
 Polyclonal Antibody (Human), APC)
 Polyclonal Antibody (Human), Biotinylated)
 Polyclonal Antibody (Human), Cy3)
 Polyclonal Antibody (Human), FITC)
 Polyclonal Antibody (Human), HRP)
 Polyclonal Antibody (Human), PE)
 IgG #1, aff pure)
 Polyclonal Antibody (Human), APC-Cy7)
 Antibody)
 (pORF))
 (pORF))
 (pORF))
 antibody)
)
)
)
)
)
 Antibody)
 (pPB-C-His))
 (pPB-N-His))
 (pPM-C-HA))
 (pPM-C-His))
 (Target 1))
 (Target 2))
 (Target 3))
 (Target 1))
 (Target 2))
 (Target 3))
 (Target 1))
 (Target 2))
 (Target 3))
 (pPB-C-His))
 (pPB-N-His))
 (pPM-C-HA))
 (pPM-C-His))
 (pPB-C-His))
 (pPB-N-His))
 (pPM-C-HA))
 (pPM-C-His))
 Antibody)
 (CMV) (pLenti-GIII-CMV))
 (UbC) (pLenti-GIII-UbC))
 (EF1a) (pLenti-GIII-EF1a))
 Antibody (HRP))
 Antibody (FITC))
 Antibody (Biotin))
 Antibody)
)
)
)
 ELISA Kit)
 ELISA kit)
 CLIA Kit)
 (Target 1))
 (Target 2))
 (Target 3))
 (CMV) (pLenti-GIII-CMV-C-term-HA))
 (CMV) (pLenti-GIII-CMV-GFP-2A-Puro))
 (CMV) (pLenti-GIII-CMV-RFP-2A-Puro))
 (Target 1))
 (Target 2))
 (Target 3))
 (Target 1))
 (Target 2))
 (Target 3))
)
CLIA Kit)
)
